interleukin-8 and hexamethylene-bisacetamide

interleukin-8 has been researched along with hexamethylene-bisacetamide* in 1 studies

Other Studies

1 other study(ies) available for interleukin-8 and hexamethylene-bisacetamide

ArticleYear
Anti-Cancer Drug HMBA Acts as an Adjuvant during Intracellular Bacterial Infections by Inducing Type I IFN through STING.
    Journal of immunology (Baltimore, Md. : 1950), 2017, 10-01, Volume: 199, Issue:7

    The anti-proliferative agent hexamethylene bisacetamide (HMBA) belongs to a class of hybrid bipolar compounds developed more than 30 y ago for their ability to induce terminal differentiation of transformed cells. Recently, HMBA has also been shown to trigger HIV transcription from latently infected cells, via a CDK9/HMBA inducible protein-1 dependent process. However, the effect of HMBA on the immune response has not been explored. We observed that pretreatment of human peripheral blood mononuclear cells with HMBA led to a markedly increased production of IL-12 and IFN-γ, but not of TNF-α, IL-6, and IL-8 upon subsequent infection with

    Topics: Acetamides; Adjuvants, Immunologic; Burkholderia pseudomallei; Cell Line; Cells, Cultured; Cytoplasm; Epithelial Cells; Humans; Interferon Regulatory Factor-3; Interferon Type I; Interferon-gamma; Interleukin-12; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Membrane Proteins; Nucleotidyltransferases; Salmonella enterica; Signal Transduction; Tumor Necrosis Factor-alpha

2017